Nvx-cov2373
Nvx-cov2373 Uses, Dosage, Side Effects, Food Interaction and all others data.
Nvx-cov2373 is a SARS-CoV-2 rS vaccine candidate and was shown to have high immunogenicity in studies. The vaccine is created from the genetic sequence of COVID-19 and the antigen derived from the virus spike protein is generated using recombinant nanoparticle technology. The vaccine was developed and tested by Novavax. As of May 2020, the company is pursuing a Phase 1 clinical trial (NCT04368988) to test the vaccine.
| Trade Name | Nvx-cov2373 |
| Generic | NVX-CoV2373 |
| NVX-CoV2373 Other Names | SARS-CoV-2 rS Nanoparticle Vaccine |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | September 19, 2023 at 7:00 am |
Innovators Monograph
You find simplified version here Nvx-cov2373
